HD
47
9
NTAP
64
-9
DVA
72
-3
LOW
58
-3
MPC
41
2
NWSA
84
4
WMT
75
13
CMS
67
2
SJM
39
3
GOOG
75
2
AVY
75
-3
BXP
54
-6
AES
79
9
CMI
62
-3
SO
82
-2
BIIB
48
-3
HP
30
-2
WBA
38
3
SPG
64
-2
WY
33
-4
HD
47
9
NTAP
64
-9
DVA
72
-3
LOW
58
-3
MPC
41
2
NWSA
84
4
WMT
75
13
CMS
67
2
SJM
39
3
GOOG
75
2
AVY
75
-3
BXP
54
-6
AES
79
9
CMI
62
-3
SO
82
-2
BIIB
48
-3
HP
30
-2
WBA
38
3
SPG
64
-2
WY
33
-4
Financhill
Back

Capricor Therapeutics 10K Form

Buy
73

CAPR
Capricor Therapeutics

Last Price:
6.22
Seasonality Move:
8.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CAPR News And Ratings

See the #1 stock for the next 7 days that we like better than CAPR

CAPR Financial Statistics

Sales & Book Value

Annual Sales: $25.18M
Cash Flow: $-1.93M
Price / Cash Flow: 0
Annual Sales: $0.58
Price / Book: 10.7

Profitability

EPS (TTM): -0.83000
Net Income (TTM): $-24.31M
Gross Margin: $500K
Return on Equity: -252.29%
Return on Assets: -49.58%

Capricor Therapeutics Earnings Forecast

Key Capricor Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 6 years for CAPR is 100.00%.
  • The Selling, General & Administrative Expenses for CAPR have been equal to 49.11% of Gross Profit Margin.
  • The Research & Development expenses have been 144.76% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CAPR is -88.52% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

Capricor Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CAPR
CUSIP: 14070B
Website: capricor.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.57
Quick Ratio: 1.53

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CAPR Technical Analysis vs Fundamental Analysis

Buy
73
Capricor Therapeutics (CAPR) is a Buy

Is Capricor Therapeutics a Buy or a Sell?